ATLANTA and IRVINE, Calif., May 6, 2011 /PRNewswire/ —
CryoLife, Inc. (NYSE:
CRY), an implantable biological medical device and
cardiovascular tissue processing company, today announced the final
results of its tender offer, including proration results, through
its wholly owned subsidiary CL Falcon, Inc., for 49.9 percent of
the outstanding shares of Cardiogenesis Corporation
(“Cardiogenesis”) (OTCQB: CGCP). The tender offer expired at
12:00 midnight, Eastern Time, at the end of the day on Monday, May
2, 2011.
Based on information provided by Computershare Inc., the
depositary and paying agent for the tender offer, a total of
38,788,414 shares of Cardiogenesis’ common stock, representing
approximately 83.4 percent of Cardiogenesis’ outstanding common
stock, were validly tendered and not withdrawn in the tender offer.
Of those shares tendered, 23,221,166 shares of Cardiogenesis
common stock, representing approximately 49.9 percent of
Cardiogenesis’ outstanding common stock, were acquired at $0.457
per share in the tender offer, less applicable withholdings.
The final proration factor for the tender offer was
approximately 59.9 percent. The depositary for the tender
offer, Computershare, Inc., has paid for the shares accepted for
purchase and will promptly return all other shares tendered and not
accepted for purchase. Immediately after consummation of the
tender offer, based on information provided by Computershare,
approximately 46,535,403 shares of Cardiogenesis’ common stock were
issued and outstanding. Investor questions concerning the
tender offer may be directed to the information agent, Georgeson,
at (800) 676-0098.
As a result of the successful completion of the tender offer,
Cardiogenesis has scheduled a special meeting of shareholders to
consider and vote upon the proposed merger between Cardiogenesis
and CryoLife. Ca
‘/>”/>
